Pearsanta, a subsidiary of Aditxt, has recently acquired the Mitomic testing platform from MDNA Life Sciences. The transaction, valued at approximately $25 million, is a strategic expansion for Pearsanta, enhancing its capabilities in early disease and cancer detection, particularly in women’s health, focusing on conditions such as endometriosis and ovarian cancer.
The Mitomic technology utilizes mitochondrial DNA (mtDNA) to detect diseases at early stages. This method provides a less invasive option for disease detection, using mtDNA mutations as biomarkers. The acquisition includes assets that extend beyond oncology, addressing various health issues.
A notable aspect of this acquisition is the Mitomic Endometriosis Test (MET), a blood-based assay under development for the diagnosis of endometriosis. The MET is designed to offer early diagnostic capabilities, potentially reducing the time taken to diagnose endometriosis.
Additionally, the acquisition includes the development of the Mitomic Prostate Test (MPT) for diagnosing prostate cancer and a pipeline of tests targeting various other cancers such as ovarian, lung, and breast cancer. These developments are part of Pearsanta’s efforts to provide non-invasive or minimally invasive testing options at early stages of disease.
Ernie Lee, CEO of Pearsanta, emphasized the significance of this transaction for the business: “Integrating these assets into our portfolio represents a significant milestone for Pearsanta. It could open a world of possibilities to harness the unique power of Mitochondrial DNA in disease detection and precision medicine. We believe that Mitochondrial DNA is an exceptional liquid biopsy technology, and our entry into this transaction underscores our dedication to pioneering innovations that can significantly impact global patient care. Adding this asset portfolio represents a major stride forward in our potential to empower individuals with the knowledge and tools they need to take control of their health. Our focus remains firmly on delivering innovative solutions that enhance healthcare accessibility and transform the lives of individuals.”
Chris Mitton, MDNA’s CEO, commented on the transaction: “We believe that this technology has the potential to redefine the landscape of disease diagnostics and that Pearsanta’s platform, supported by its expertise and resources, can enable it to realize its full potential.”
This acquisition is in line with Aditxt’s broader mission to advance health innovations. Aditxt’s recent agreement to acquire Evofem Biosciences further demonstrates its commitment to expanding its healthcare offerings. The acquisition deal includes a combination of Aditxt common stock, Pearsanta preferred stock, and additional payments.